ArticleCurrent treatment options in oncology2011
Management of meningeal neoplasms: meningiomas and hemangiopericytomas.
Article in Current treatment options in oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Extracranial Intraluminal Extension of Atypical Meningioma within the Internal Jugular Vein.Case reports in otolaryngology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
opinion statementMeningiomas are the most frequently diagnosed primary brain tumor accounting for nearly one third of all primary brain and central nervous system tumors reported in the United States. According to the 2007 World Health Organization classification scheme, Grade I meningiomas are benign, Grade II defines atypical lesions, while Grade III meningiomas are anaplastic or frankly malignant tumors. Not surprisingly, Grade II and III meningiomas usually follow a more aggressive course and confer a worse prognosis. The diagnosis of meningioma is confirmed by pathologic examination and improvements in imaging help to better define when observation versus intervention is appropriate. Surgical resection, when possible, is the mainstay of treatment. When complete resection is not possible, stereotactic radiosurgery (SRS) can result in disease stabilization. Chemotherapy has yet to result in reproducible long-term disease free or overall survival benefits. Biologic agents remain under investigation. Hemangiopericytomas are rare dural based sarcomas. These tumors are known for their aggressiveness, high recurrence rates and their proclivity to metastasize to extracranial locations. Gross total resection when feasible remains the treatment of choice.
Indexed as
Identifiers
21537847What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.